Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 11,166 shares of Intersect ENT stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $33.47, for a total transaction of $373,726.02. Following the completion of the sale, the insider now owns 495,849 shares of the company’s stock, valued at $16,596,066.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Intersect ENT Inc (XENT) traded up $0.55 during midday trading on Friday, reaching $34.55. 299,179 shares of the company’s stock traded hands, compared to its average volume of 225,941. Intersect ENT Inc has a twelve month low of $11.75 and a twelve month high of $35.34. The firm has a market cap of $1,001.50, a PE ratio of -54.84 and a beta of 0.67.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The firm had revenue of $22.31 million during the quarter, compared to analysts’ expectations of $21.53 million. During the same period in the previous year, the business posted ($0.22) EPS. The business’s revenue was up 20.8% compared to the same quarter last year. sell-side analysts forecast that Intersect ENT Inc will post -0.63 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of XENT. Great West Life Assurance Co. Can acquired a new position in shares of Intersect ENT in the 3rd quarter valued at $116,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Intersect ENT in the 3rd quarter valued at $117,000. Bank of Montreal Can acquired a new position in shares of Intersect ENT in the 4th quarter valued at $135,000. Legal & General Group Plc lifted its stake in shares of Intersect ENT by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares during the period. Finally, Moors & Cabot Inc. acquired a new position in shares of Intersect ENT in the 2nd quarter valued at $205,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.
Several analysts have commented on XENT shares. BidaskClub cut shares of Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Canaccord Genuity restated a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a research note on Monday, December 11th. JPMorgan Chase & Co. upgraded shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Guggenheim restated a “buy” rating and set a $41.00 price objective on shares of Intersect ENT in a research note on Friday, December 15th. Finally, Zacks Investment Research cut shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.38.
TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/20/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-11166-shares-of-stock.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.